Panos G Christakis1, Dongyu Zhang2, Donald L Budenz3, Keith Barton4, James C Tsai5, Iqbal I K Ahmed1. 1. Department of Ophthalmology and Vision Sciences, University of Toronto Faculty of Medicine, Toronto, Canada. 2. Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina. 3. Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina; Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: dbudenz@med.unc.edu. 4. NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom. 5. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York Eye and Ear Infirmary of Mount Sinai, New York, New York.
Abstract
PURPOSE: To determine the relative efficacy of the Ahmed-FP7 and Baerveldt BG101-350 implants. DESIGN: Pooled analysis of 2 multicenter, randomized clinical trials. METHODS: A total of 514 patients aged 18 or older with uncontrolled glaucoma that had failed or were at high risk of failing trabeculectomy were randomized to receive an Ahmed implant (n = 267) or Baerveldt implant (n = 247). Cumulative failure rates (using an intraocular pressure [IOP] target of 6-18 mm Hg inclusive), de novo glaucoma surgery rates, mean IOP, mean glaucoma medication use, and visual acuity were compared. RESULTS: Baseline characteristics were similar between groups. Mean preoperative IOP of the study population was 31.5 ± 11.3 mm Hg on an average of 3.3 ± 1.1 glaucoma medications. At 5 years, mean IOP was 15.8 ± 5.2 mm Hg in the Ahmed group and 13.2 ± 4.7 mm Hg in the Baerveldt group (P < .001). Mean glaucoma medication use was 1.9 ± 1.5 in the Ahmed group and 1.5 ± 1.4 in the Baerveldt group (P = .007). The cumulative failure rate at 5 years was 49% in the Ahmed group and 37% in the Baerveldt group (P = .007). High IOP was the most common reason for failure in both groups, and de novo glaucoma surgery was required in 16% of the Ahmed group and 8% of the Baerveldt group (P = .006). Failure owing to hypotony occurred in 0.4% of the Ahmed group and 4.5% of the Baerveldt group (P = .002). Visual outcomes were similar between groups (P = .90). CONCLUSIONS: The Baerveldt group had a lower failure rate, lower rate of de novo glaucoma surgery, and lower mean IOP on fewer medications than the Ahmed group. Baerveldt implantation carried a higher risk of hypotony.
RCT Entities:
PURPOSE: To determine the relative efficacy of the Ahmed-FP7 and Baerveldt BG101-350 implants. DESIGN: Pooled analysis of 2 multicenter, randomized clinical trials. METHODS: A total of 514 patients aged 18 or older with uncontrolled glaucoma that had failed or were at high risk of failing trabeculectomy were randomized to receive an Ahmed implant (n = 267) or Baerveldt implant (n = 247). Cumulative failure rates (using an intraocular pressure [IOP] target of 6-18 mm Hg inclusive), de novo glaucoma surgery rates, mean IOP, mean glaucoma medication use, and visual acuity were compared. RESULTS: Baseline characteristics were similar between groups. Mean preoperative IOP of the study population was 31.5 ± 11.3 mm Hg on an average of 3.3 ± 1.1 glaucoma medications. At 5 years, mean IOP was 15.8 ± 5.2 mm Hg in the Ahmed group and 13.2 ± 4.7 mm Hg in the Baerveldt group (P < .001). Mean glaucoma medication use was 1.9 ± 1.5 in the Ahmed group and 1.5 ± 1.4 in the Baerveldt group (P = .007). The cumulative failure rate at 5 years was 49% in the Ahmed group and 37% in the Baerveldt group (P = .007). High IOP was the most common reason for failure in both groups, and de novo glaucoma surgery was required in 16% of the Ahmed group and 8% of the Baerveldt group (P = .006). Failure owing to hypotony occurred in 0.4% of the Ahmed group and 4.5% of the Baerveldt group (P = .002). Visual outcomes were similar between groups (P = .90). CONCLUSIONS: The Baerveldt group had a lower failure rate, lower rate of de novo glaucoma surgery, and lower mean IOP on fewer medications than the Ahmed group. Baerveldt implantation carried a higher risk of hypotony.
Authors: Tigran Kostanyan; Tarek Shazly; Kevin B Kaplowitz; Steven Z Wang; Sushma Kola; Eric N Brown; Nils A Loewen Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-09-25 Impact factor: 3.117
Authors: Mario Montelongo; Francesc March de Ribot; Earl Randy Craven; William Eric Sponsel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2020-11-11 Impact factor: 3.117
Authors: Felix F Kung; Catherine G Knier; Armin Garmany; Camilo A Mejia; Jason M Sargent; Sepideh Jamali Dogahe; Nouran Sabbagh; David O Hodge; Cheryl L Khanna Journal: J Glaucoma Date: 2021-06-01 Impact factor: 2.290
Authors: André S Pollmann; Amit V Mishra; Maria Gabriela Campos-Baniak; R Rishi Gupta; Brennan D Eadie Journal: Am J Ophthalmol Case Rep Date: 2020-05-30